Liver Fat Content Measurement with Quantitative CT Validated against                     MRI Proton Density Fat Fraction: A Prospective Study of 400 Healthy                     Volunteers

AbstractNon-alcoholic steatohepatitis is frequently associated with diabetes and may cause progressive liver disease. Current treatment options are limited. Here we report on a prospective, randomised, double-blind, placebo-controlled trial of two doses of HTD1801 (berberine ursodeoxycholate, an ionic salt of berberine and ursodeoxycholic acid), versus placebo that was conducted in 100 subjects with fatty liver disease and diabetes (NCT03656744). Treatment was for 18 weeks with a primary endpoint of reduction in liver fat content measured by magnetic resonance imaging proton density fat fraction. Key secondary endpoints included improvement in glycemic control, liver-associated enzymes and safety. The pre-specified primary endpoint was met. Thus, subjects receiving 1000 mg twice a day of berberine ursodeoxycholate had significantly greater reduction in liver fat content than in placebo recipients (mean absolute decrease −4.8% vs. −2.0% (p = 0.011). Compared to placebo, subjects receiving this dose also experienced significant improvement in glycemic control as well as reductions in liver-associated enzymes and significant weight loss. Diarrhea and abdominal discomfort were the most frequently reported adverse events. We conclude that berberine ursodeoxycholate has a broad spectrum of metabolic activity in patients with presumed NASH and diabetes. It is relatively well tolerated and merits further development as a treatment for NASH with diabetes.

Download Full-text

Speed of sound ultrasound: comparison with proton density fat fraction assessed with Dixon MRI for fat content quantification of the lower extremity

European Radiology ◽

10.1007/s00330-020-06885-8 ◽

2020 ◽

Vol 30 (10) ◽

pp. 5272-5280 ◽

Cited By ~ 1

Author(s):

Lisa Ruby ◽

Ahmet Kunut ◽

Dominik N. Nakhostin ◽

Florian A. Huber ◽

Tim Finkenstaedt ◽

...

Keyword(s):

Lower Extremity ◽

Speed Of Sound ◽

Fat Content ◽

Proton Density ◽

Proton Density Fat Fraction ◽

Fat Fraction

Download Full-text

Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction

Therapeutic Advances in Gastroenterology ◽

10.1177/1756284819879047 ◽

2019 ◽

Vol 12 ◽

pp. 175628481987904 ◽

Cited By ~ 2

Author(s):

Junzhao Ye ◽

Yanqin Wu ◽

Fuxi Li ◽

Tingfeng Wu ◽

Congxiang Shao ◽

...

Keyword(s):

Clinical Trial ◽

Conventional Care ◽

Liver Fat ◽

Proton Density ◽

Trial Registry ◽

Resonance Imaging ◽

Clinical Trial Registry ◽

Liver Fat Content ◽

Nonalcoholic Fatty Liver ◽

Fat Fraction

Background: The liver effect of orlistat as a weight control treatment in patients with nonalcoholic fatty liver disease (NAFLD) with obesity remains undetermined. This study quantified liver fat improvement by orlistat in a Chinese cohort with NAFLD accompanied by obesity, diagnosed by a lower body mass index threshold than that for White patients. Materials and methods: We conducted a parallel-group, open-label, 24-week, randomized clinical trial registered at the Chinese Clinical Trial Registry (ChiCTR-IPR-17012258). Obese participants with NAFLD were randomized 1:1.5 to the intervention group with orlistat or conventional care. Liver fat quantification was assessed by magnetic resonance imaging-based proton density fat fraction with Dixon sequence. Results: Overall, 170 ( n = 68, orlistat 120 mg three times/day and n = 102, conventional therapy) and 130 patients with NAFLD ( n = 56, orlistat and n = 74, conventional therapy) were included for intention-to-treat (ITT) and per-protocol (PP) analysis, respectively. Orlistat reduced liver fat content to a greater degree than conventional care [−5.45% versus −1.96%, p < 0.001 (ITT analysis) and −6.66% versus −2.68%, p < 0.001 (PP analysis)]. The 6-month rate of decrease in steatosis grades was higher in the orlistat group [45.6% versus 22.5% (ITT analysis), 57.4% versus 30.3% (PP analysis), both p < 0.001]. Multivariate logistic regression analysis identified orlistat treatment [odds ratio (OR) = 2.4; 95% confidence interval (CI) 1.1–5.6, p = 0.036] as an independent predictor of steatosis improvement. Among patients with orlistat therapy, weight loss (OR = 1.2, 95% CI 1.1–1.4, p = 0.040) and severe steatosis (OR = 6.7, 95% CI: 1.1–40.3, p = 0.03) remained predictive of steatosis improvement. Conclusions: Orlistat can effectively promote steatosis improvement and may serve as a treatment option for controlling NAFLD. Chinese Clinical Trial Registry identifier: ChiCTR-IPR-17012258

Download Full-text

Utility of magnetic resonance proton density fat fraction technique in quantification of liver fat in living donors for liver transplantation

Egyptian Journal of Radiology and Nuclear Medicine ◽

10.1186/s43055-019-0061-4 ◽

2019 ◽

Vol 50 (1) ◽

Author(s):

Fatma Mohamed Sherif ◽

Sabry Alameldeen Elmogy ◽

Rihame Mohamed Abd EL-wahab ◽

Mohamed Abdel Wahab

Keyword(s):

Liver Transplantation ◽

Magnetic Resonance ◽

Confidence Interval ◽

Hepatic Steatosis ◽

Quantitative Evaluation ◽

Liver Fat ◽

Proton Density ◽

Proton Density Fat Fraction ◽

Fat Fraction ◽

Living Liver Donors

Abstract Background Hepatic steatosis in living donors for liver transplantation causes morbidity of both donor and recipient. This study aims at evaluating magnetic resonance proton density fat fraction technique (MR PDFF) in quantitative evaluation of living donor’s hepatic steatosis compared to histopathology. Results The examined potential living liver donors’ liver biopsies revealed hepatic steatosis < 5% (grade 0) in 40 donors and 5–10% (grade 1) in 7 donors. MR PDFF technique with IDEAL sequence showed excellent results for prediction and quantitative evaluation of liver fat with sensitivity, specificity, and accuracy of 85.7%, 97.5%, and 95.7%, respectively, compared to histopathology (95% confidence interval 0.98–1.01). There was an excellent inter-reader agreement between both readers in estimation of MR liver fat fraction (r = 0.969 at 95% confidence interval 0.946–0.983). Conclusion Noninvasive hepatic MR PDFF technique with IDEAL sequence is a precise reliable technique for pre-operative quantitative assessment of hepatic steatosis in potential living liver donors.

Download Full-text